Drug or technology

Antibodies, Viral

7 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 4, 2026 · JOURNAL ARTICLE

Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents.

Human Vaccines & Immunotherapeutics

A sound comparative immunogenicity study in a vulnerable population showing equivalent responses between two widely used vaccines, but limited by cross-sectional design, surrogate endpoints, and lack of clinical outcome data.

PromisingDennis Wilk Debbie Keresztesy Antibodies, Neutralizing

Reported

Sampling window post-vaccination10-30 d

AUG 4, 2026 · JOURNAL ARTICLE

Advancing human metapneumovirus vaccine development through fusion protein stabilization.

Virology

This is a narrative review synthesizing structure-guided protein engineering strategies and preclinical immunogenicity data, raising mechanistic questions about pre-F stabilization rather than reporting a definitive clinical or confirmatory experimental result.

Hypothesis-GeneratingVaccine Development Antibodies, Neutralizing Viral Vaccines

Study details

DesignNarrative review

JUL 9, 2026 · JOURNAL ARTICLE

T cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2.

Human Vaccines & Immunotherapeutics

A mechanistic study using genetically modified mouse models demonstrating that T cell-associated immunity from a heterologous rBCG/protein vaccine confers cross-variant protection against SARS-CoV-2 JN.1, with clear immunological endpoints but limited to preclinical animal models.

PromisingAlba M Gimenez Karla K S Ramos Antibodies, Neutralizing

Reported

Study population6- to 8-week-old K18-hACE2 mice and knockou…

JUN 21, 2026 · JOURNAL ARTICLE

Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.

Emerging Microbes & Infections

A narrative review synthesizing current knowledge on dengue therapeutics (vaccines, antivirals, monoclonal antibodies) without original data or systematic analysis, offering translational context on development stage and mechanistic insight for clinical and research audiences.

Expert GuidanceDengue Vaccines Antibodies, Monoclonal Hawa Sophia Bouzidi

Reported

Global reported case numbers (202…over 6.5 million

Deaths reported (2025 to date)1900

Genomic homology between serotypesapproximately 65%

JUN 12, 2026 · JOURNAL ARTICLE

Causal associations between antibody-mediated immune responses to infectious agents and cardiovascular inflammatory diseases: A Mendelian randomization study based on UK Biobank and FinnGen.

Human Vaccines & Immunotherapeutics

Mendelian randomization study identifying genetic associations between pathogen antibodies and cardiovascular inflammatory diseases; findings under strict threshold represent hypothesis-generating evidence requiring validation in rigorous designs and diverse populations.

PreliminaryShikun Sun Antibody-mediated Immune Responses to Infectious Agents Jia Lin

Reported

HHV-7 U14 with myocarditis – Odds…2.049

HHV-7 U14 with myocarditis – 95%…1.325–3.168

HHV-7 U14 with myocarditis – p-va…0.001

JUN 11, 2026 · JOURNAL ARTICLE

Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial.

Human Vaccines & Immunotherapeutics

Phase 1/2 trial demonstrating that AS03-adjuvanted H5N8 vaccine met FDA immunogenicity criteria with acceptable safety in adults, but lacks efficacy data and comparative effectiveness evidence needed for practice-changing claims.

PromisingVinay Gupta Influenza Vaccines Andrew Hastie

Reported

Sample size (vaccinated)518

Primary endpoint timepointday 43

Hemagglutinin antigen dose tested3.75 or 7.50 µg

JUN 4, 2026 · JOURNAL ARTICLE

Immune response to rotavirus vaccines in low- and middle-income countries: Challenges and perspectives.

Human Vaccines & Immunotherapeutics

A narrative review synthesizing current knowledge on rotavirus vaccine immunology in LMICs and HICs, identifying research priorities but not presenting primary experimental or clinical trial data to support practice changes.

Expert GuidanceOmar Rossi Vaccine Efficacy Melania Della Peruta

Reported

Vaccine efficacy in high-income c…85–90%

Vaccine efficacy in low- and midd…45–65%

Annual rotavirus deaths in childr…120,000 to 200,000